Eli Lilly Gets 6 Month Extension for Cymbalta
Eli Lilly can enjoy competition-free Cymbalta sales for 6 months longer. Thanks to FDA's pediatric-exclusivity program, the blockbuster antidepressant won't face generic rivals until next December, rather than June, when its patent expires. The extension comes as a reward for testing Cymbalta in children and adolescents.
That's a big deal for Lilly, which reaped $3.2 billion from Cymbalta sales in the U.S. last year. The prospect of an extra $1.5 billion in sales is well worth the cost of studying Cymbalta in children. Or more, even: for the first quarter of 2012, U.S. sales rose by 24% to $857.6 million, partly because of higher prices. The company's patent-cliff losses are among the worst in pharma, so every billion is a big help.
What Lilly won't get from its two pediatric studies is approval to market Cymbalta for use in kids, the company says. The studies found that Cymbalta didn't beat placebo at treating depression in young people. (Neither did Lilly's old-standby antidepressant Prozac, also tested in the studies.)
Browse by category
- ROVI CM - Contract manufacturing Services for injectables and solid forms in our two FDA-approved & GMP-certified manufacturing plants! Actively looking for clients NOW!
- Eriochem have added 3 dossiers to their profile - Melphalan, Pemetrexed and Zoledronic acid (all in CTD)! Connect with them now!
- Glenmark Generics have updated their product details - make an enquiry here!
- ACIC Europe have updated their product list - check it out now!
- Abdi Ibrahim have a ready MA for Memantine in France, Italy and Spain - looking for distributors now...